DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth is viewed positively because its vertically integrated chronic-care model combines FDA-cleared devices, proprietary data, AI, and coaching, which supports stronger engagement, better outcomes, and potentially superior ROI versus software-only peers. Commercial momentum is improving through expanded access to 175mn+ covered lives, 116mn lives via Solera and Amwell, a top-5 health plan expansion into hypertension that could triple revenue from that customer, and a Fortune 50 win with 100k eligible employees, while $13mn of committed/late-stage ARR and a $127mn pipeline indicate meaningful scaling potential. The 2024 Twill acquisition, DarioIQ’s expected 10-15% incremental recurring revenue uplift, and management’s plan for ~10% OpEx reductions in 2027 and cash-flow breakeven by end of 2027 further strengthen the fundamental upside case.

DarioHealth is facing a weak demand backdrop that is suppressing revenue growth, as 2Q revenue of $5.2M missed estimates and both B2C and B2B underperformed, even though gross margin held at 65% and B2B margins stayed near 80%. The company’s improving cost discipline after the Twill acquisition and lower non-GAAP expenses help narrow losses, but adj. EBITDA loss of $5.3M still missed expectations and profitability remains dependent on stronger revenue acceleration from $13M of new contracted ARR starting in 4Q and ramping through 2027. With limited visibility in B2B2C and partnerships, churn risk, and the likelihood that future capital raises could be dilutive, the fundamental setup still points to fragile execution and uncertain path to break-even by 4Q26/1Q27.